CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Evaluation of erectile dysfunctionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01843218
NCT01843218N/ACompleted
CompareCT.gov

Erectile Rating During the Treatment of Rectal Cancers Localized. Exploratory Study

Institut Bergonié·interventional·Posted Apr 30, 2013·Updated Sep 23, 2025

In Brief

A clinical study evaluating Evaluation of erectile dysfunction for Rectal Cancer Stage I. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Sexual dysfunction is a common side effect of medical and surgical treatments for rectal cancer. It can manifest as ejaculation disorders or erectile dysfunction. Due to the modesty of both patients and doctors, these disorders are poorly understood and probably underestimated at present. Aim : Objectively assess the presence of erectile dysfunction induced by medical and surgical treatment of rectal cancer three months after surgery. These objective data will be obtained using the RIGISCAN® PLUS system coupled with polysomnographic recording.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer Stage I
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2013
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2014
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.2 years ago

Interventions

Evaluation of erectile dysfunctionother

Assessment (at night) of erctile dysfunction using R/P recording (RIGISCAN® PLUS / polysomonography)